TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or post-menopausal female.~* Waist circumference ≥102cm for male, ≥ 88cm for female.~* Atherogenic dislipidaemia inadequately controlled despite Therapeutic Lifestyle Change (TLC) recommendations (diet and exercise).~* 150≤ fasting TG ≤ 600 mg/dL (1.69 ≤ fasting TG ≤ 6.78 mmol/L) at V2.~* Fasting HDL-C ≤ 40 mg/dL (≤ 1.03 mmol/L) for male, HDL-C ≤ 45 mg/dL (≤ 1.16 mmol/L) for female at V2.~Exclusion Criteria:~* Body Mass Index (BMI) ≥ 40 kg/m².~* Blood Pressure \> 160 / 95 mmHg.~* Type I or type II Diabetes Mellitus.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- GFT505 80mg (Type: EXPERIMENTAL): None
- Matching placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound for Neuraxial Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Surgery under spinal, epidural or combined spinal-epidural anesthesia.~* Surgery under general anesthesia and preoperative placement of epidural catheter for postoperative analgesia.~* ASA 1-3.~Exclusion Criteria:~* History of lumbar spinal surgery.~* Low back pain at the time of anesthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ultrasound (Type: EXPERIMENTAL): None
- Landmarks (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atomoxetine and Oxybutynin in Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criterion:~- AHI \> 20~Exclusion Criteria:~* Any medical condition other than well controlled hypertension.~* Any medication known to influence breathing, sleep/arousal or muscle physiology.~* Claustrophobia.~* Inability to sleep supine.~* Allergy to lidocaine, Oxymetazoline HCl, atomoxetine/oxybutynin.~* Individuals with underlying cardiac disease, such as arrhythmias.~* Individuals taking psychiatric medications, such as atomoxetine, or any of the studied medications for medical care.~* History of seizures~* For women: Pregnancy.~* History of panic disorder / hyperventilation syndrome / Attention deficit-hyperactivity disorder (ADHD) / autism

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 2 hours before bedtime
- Combination product of Atomoxetine and Oxybutynin (Type: ACTIVE_COMPARATOR): Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of COPD with symptoms for more than 2 years.~* Smoking history of 10 or more pack years~* A history of at least one COPD exacerbation requiring a course of oral steroids and/or antibiotics within 1-12 months before first visit.~Exclusion Criteria:~* A history of asthma~* Patients taking oral steroids~* Any significant disease or disorder that may jeopardize the safety of the patient

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent must be obtained from each patient prior to study entry.~2. Age \>/= 14 years of age. Life expectancy greater than or equal to 6 months. PS \</= 2 (ECOG).~3. Patients with histologically confirmed squamous cell carcinoma of the penis who present with clinical stage (T(subscript)xN(subscript)2-3M(subscript)0) disease based on the 1987-1992 TNM Staging System and meeting the additional clinicopathologic criteria as defined in the protocol (section 3.1).~4. Patients must have adequate physiologic reserve as evidenced by: absolute neutrophil count (ANC) \>/= 1,500/mm3(superscript) and platelet count \>/= 100,000/mm3. Transaminases \</= 2 times the upper limit of normal. Conjugated bilirubin \</= 1.5mg/dL. Creatinine clearance (either calculated or measured) of \>/= 40ml/minute.~5. No evidence of active ischemia on the EKG and, for patients with significant prior coronary artery disease history, an ejection fraction of more than 40%. No evidence of severe conduction abnormalities on EKG.~Exclusion Criteria:~1. Patients with uncontrolled infection or CNS disease.~2. Distant metastasis (TNM stage M1, i.e., lung, bone, other visceral sites, lymph node metastasis above the aortic bifurcation).~3. Patients with clinically negative inguinal examinations or those with palpable adenopathy not meeting pathological or clinical criteria (i.e., minimal nodal metastasis or false positive inguinal examination).~4. Prior systemic chemotherapy for penile carcinoma.~5. Prior radiation therapy to inguinal or pelvic lymph nodes.

- Gender: MALE
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cisplatin + Ifosfamide + Paclitaxel (Type: EXPERIMENTAL): Cisplatin 25 mg/m\^2 IV Days 1-3; Ifosfamide 1200 mg/m\^2 IV Days 1-3; Paclitaxel 175 mg/m\^2 IV Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A current clinical diagnosis of Chronic Obstructive Pulmonary Disease~* Documented Chronic Obstructive Pulmonary Disease symptoms for more than 2 years~* A smoking history of at least 10 pack years~Exclusion Criteria:~* History and/or current clinical diagnosis of asthma~* History and/or current clinical diagnosis of atopic diseases such as allergic rhinitis

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Symbicort Turbuhaler 160/4.5 microgram, 2 inhalations twice daily
- 2 (Type: ACTIVE_COMPARATOR): Oxis Turbuhaler 4.5 microgram, 2 inhalations twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-64 years~* Duration of T1D ≥ 3 years~* Use of CSII or MDI therapy for ≥ 6 months~* Current use of Novorapid (change from another fast-acting insulin to Novorapid prior to study initiation is allowed)~* HbA1c ≤ 8.0%~* Regular use of carbohydrate counting in the judgement of the investigator~Exclusion Criteria:~* Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start~* History of allergy or intolerance to glucagon or glucagon-like products~* Patients with pheochromocytoma~* Clinically significant ECG abnormalities~* Females who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (sterilization, intrauterine device, contraceptive pill, patch or injection)~* Inability to understand the individual information and to give informed consent~* Current participation in another clinical trial that, in the judgment of the principle investigator, will compromise the results of the study or the safety of the subject~* Other concomitant medical or psychological condition that, according to the investigator's assessment, makes the individual unsuitable for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 80 µg s.c. dasiglucagon (Type: EXPERIMENTAL): 80 µg of dasiglucagon will be administered subcutaneously when plasma glucose levels reach 4.5 mmol/l
- 120 µg s.c. dasiglucagon (Type: EXPERIMENTAL): 120 µg of dasiglucagon will be administered subcutaneously when plasma glucose levels reach 4.5 mmol/l
- 15 g oral carbohydrate (dextrose tablets) (Type: ACTIVE_COMPARATOR): 15 g of oral carbohydrate (dextrose tablets) will be administered when plasma glucose levels reach 4.5 mmol/l

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* men \> 18 and ≤ 75 years~* post-menopausal women ≤ 75 years (follicle stimulating hormone (FSH) \>30 mIU/ml, women \> 60 years FSH \> 20 mIU/ml )~* well controlled diabetes mellitus type II (glycohaemoglobin ≤ 8,0 %)~* LDL-cholesterol ≤ 160 mg/dl~* LDL-subfractions: concentration of apoB-100 in dLDL (LDL-5 und LDL-6) \> 25 mg/dl~* written informed consent~Exclusion Criteria:~* participation in a clinical trial within the last 30 d before screening- visit~* patient is unable to give written informed consent~* Body mass index \<15 kg/m² and \> 35 kg/m²~* clinical atherosclerotic disease (coronary heart disease, peripheral artery disease, carotid artery disease)~* malignoma~* uncontrolled arterial hypertension (\>160/\>100 mmHg)~* clinically relevant disease of liver and/or kidneys~* clinically relevant endocrinally or hematologic problems~* allergy to study medication (Ezetimibe and/or Simvastatin)~* alcohol- or drug abuse~* laboratory: alanine aminotransferase, aspartate aminotransferase, total bilirubin \> 3 x ULN, creatine kinase \> 5 x ULN~* Concurrent treatment with potent CYP3A4-inhibitors (e.g. itraconazole, ketoconazole, HIV-protease-inhibitors, erythromycin, clarithromycin, telithromycin und nefazodone)~* other relevant diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ezetimibe 10mg/d (Type: ACTIVE_COMPARATOR): intake of ezetimibe 10mg per day for six weeks after wash-out
- Simvastatin 20 mg per day (Type: ACTIVE_COMPARATOR): intake of simvastatin 20 mg per day for six weeks after wash-out
- Ezetimibe 10 mg/d and Simvastatin 20mg/d (Type: ACTIVE_COMPARATOR): intake of ezetimibe 10 mg and simvastatin 20 mg per day for six weeks after wash-out

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Repetitive Transcranial Magnetic Stimulation for Voices

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:~Inclusion criteria:~* Diagnosis of schizophrenia or schizoaffective disorder based on DSM-IV version of SCID~* Auditory hallucinations of spoken speech occurring at least 5 times per day where subject able to discern verbal content~* Right-handed~* At least 4 weeks on stable antipsychotic medication~Exclusion criteria:~* history of seizure (unless due to drug withdrawal or medication that is no longer prescribed)~* history of epilepsy in first degree relatives~* estimated IQ less than 80~* unable to provide informed consent~* significant unstable medical condition~* current treatment with clozapine or bupropion~* cochlear implants or other metal in the head (surgical, etc.)~* history of cardiac arrhythmia~* cardiac pacemaker~* active drug or alcohol abuse within prior 6 weeks~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- active rTMS (Type: EXPERIMENTAL): 1-Hz rTMS delivered to left temporoparietal cortex at 90% motor threshold for 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)
- sham stimulation (Type: PLACEBO_COMPARATOR): Sham stimulation delivered 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Oxytocin Treatment for Social Deficits in Children With Autism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Medically healthy outpatients between 6 and 12 years of age (cut off 12 years and 11 months)~* Intelligence Quotient \> 40~* Diagnosis of autism spectrum disorder based on the Autism Diagnostic Interview - Revised, Autism Diagnostic Observation Schedule, and DSM-IV criteria~* Clinical Global Impression severity rating of 4 or higher~* Care provider who can reliably bring subject to clinic visits, provide trustworthy ratings, and interacts with the subject on a regular basis~* Stable medications for at least 4 weeks~* No planned changes in psychosocial interventions during the trial~* Willingness to provide blood samples.~Exclusion Criteria:~* Diagnostics and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder~* Regular nasal obstruction or nosebleeds~* Active medical problems: unstable seizures, significant physical illness (e.g., serious liver, renal, or cardiac pathology)~* Sensitivity to preservatives (in particular E 216, E 218, and chlorobutanol hemihydrate)~* A genetic abnormality (e.g., Fragile X Syndrome)~* Significant hearing or vision impairments~* Habitually drinks large volumes of water~* Pregnancy, breastfeeding, or child birth within the last 6 months~* Sexually active females not using a reliable method of contraception.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Oxytocin nasal spray (Type: ACTIVE_COMPARATOR): Prior to randomization, all subjects will participate in a 1-week open-label placebo lead-in trial. Each subject will be administered the placebo nasal spray at Stanford University and then their parent will continue administering the nasal spray to the subject for 1 week at home. Each subject will then be randomly assigned either to the active group or to the placebo (stratified by gender) and will be given the appropriate nasal spray bottle and their parents will be responsible for administering 3 puffs per nostril (4 IU/puff) to their child for a total dose of 24 IU oxytocin or placebo twice daily (BID; morning and evening) for 4-weeks. On completion of this 4-week treatment trial subjects will have the option of participating in a second double-blind trial in which they will be assigned to the alternate nasal spray, to that which they received during the first 4-week trial, for an additional 4-week period.
- Placebo nasal spray (Type: PLACEBO_COMPARATOR): The placebo nasal spray bottles will be prepared by adding all of the ingredients used in the Syntocinon nasal sprays with the exception of the concentrated oxytocin solution.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of High Altitude Pulmonary Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* At least one previous episode of high altitude pulmonary edema~Exclusion Criteria:~* pulmonary arterial hypertension~* congenital heart disease~* any chronic lung disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~-Age 40 - 70 years of age.~* History of any of the following conditions (operative notes, endoscopy reports, and/or pathology reports must be reviewed locally to confirm that the candidate meets at least one of the following entry criteria).~  1. Colorectal adenoma(s) ≥ 1 cm in maximal diameter~ 2. Colorectal adenoma(s) with villous or tubulovillous histology~ 3. Colorectal adenoma(s) with high-grade dysplasia~* Willingness to avoid pregnancy or impregnate (see below) for the period of active study (1 year).~* ECOG performance status 0 or 1~* Hemoglobin greater than 95% of the lower limit of institutional normal. Platelets ≥100,000/µL.~* AST (SGOT), ALT (SGPT), alkaline phosphatase, total bilirubin, BUN, creatinine ≤ 1.5x upper limit of institutional normal.~* ANA \< 1:160~Exclusion Criteria:~* Receiving any other investigational agents.~* Presence of an active acute or chronic infection~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agents.~* History of heritable cancer syndrome (FAP, HNPCC)~* Patients with a history of auto-immune disease such as, but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, scleroderma, or multiple sclerosis.~* History of malignancy \< 5 years prior to the Registration/Randomization evaluation, excluding non-melanoma skin cancer.~* Any use of oral corticosteroids ≤ 12 weeks prior to Registration/Randomization.~* Current or planned use of immunomodulators including: Remicade, 6-MP (Mercaptopurine), Methotrexate, cyclosporine, or other immunomodulatory drugs.~* Pregnant women, because the teratogenic or abortifacient effects of the study agents remain incompletely defined. Breastfeeding women, because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study agents.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- MUC1 Poly-ICLC (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with complicated skin and skin structure infection with at least 2 signs and symptoms~* Suspected or confirmed infection due to a gram-positive organism~Exclusion Criteria:~* Complicated skin and skin structure infection due to gram-negative organisms~* Complicated skin and skin structure infections requiring more than 7 days of therapy~* Uncontrolled diabetes~* Chronic systemic immunosuppressive therapy~* AIDS with CD4 count \< 200 cells/mm3~* Uncontrolled hypertension~* Mild moderate or severe renal failure~* Severe hepatic disease~* Neutropenia~* Use of antidepressants such as SSRIs or MAOIs for 14 days before first dose of study drug~* Women who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TR-701 200 mg (Type: EXPERIMENTAL): None
- TR-701 300 mg (Type: EXPERIMENTAL): None
- TR-701 400 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete